NOVAFED Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Novafed, and what generic alternatives are available?
Novafed is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in NOVAFED is pseudoephedrine hydrochloride. There are forty-nine drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the pseudoephedrine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Novafed
A generic version of NOVAFED was approved as pseudoephedrine hydrochloride by L PERRIGO CO on February 26th, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NOVAFED?
- What are the global sales for NOVAFED?
- What is Average Wholesale Price for NOVAFED?
Summary for NOVAFED
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 36 |
| Patent Applications: | 1,488 |
| DailyMed Link: | NOVAFED at DailyMed |
US Patents and Regulatory Information for NOVAFED
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | NOVAFED | pseudoephedrine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 017603-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
